Search

Your search keyword '"Ciprofloxacin economics"' showing total 2 results
Start Over Descriptor "Ciprofloxacin economics" Publication Year Range Last 10 years
2 results on '"Ciprofloxacin economics"'

1. Two drugs facing key patent expirations and potential generic entry from July to August 2020.

Author

Friedman Y

Subjects
Anisoles economics, Ciprofloxacin economics, Dexamethasone economics, Drug Combinations, Drug Industry economics, Drug Industry legislation & jurisprudence, Drugs, Generic administration & dosage, Drugs, Generic economics, Humans, Patents as Topic, Tretinoin economics, United States, Anisoles administration & dosage, Ciprofloxacin administration & dosage, Dexamethasone administration & dosage, Tretinoin administration & dosage
Abstract

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry.

Published
2020
Full Text
View/download PDF

2. Addressing Neisseria gonorrhoeae Treatment Resistance With the DNA Gyrase A Assay: An Economic Study, United States.

Author

Wynn A and Klausner JD

Subjects
Anti-Bacterial Agents economics, Anti-Bacterial Agents pharmacology, Asymptomatic Infections, Ciprofloxacin economics, Cohort Studies, Costs and Cost Analysis, Gonorrhea drug therapy, Humans, Microbial Sensitivity Tests, United States, Ciprofloxacin pharmacology, Clinical Laboratory Techniques economics, DNA Gyrase analysis, Drug Resistance, Bacterial, Gonorrhea economics, Neisseria gonorrhoeae drug effects
Abstract

Targeted antibiotics could delay emergence of resistant Neisseria gonorrhoeae. The DNA gyrase subunit A assay predicts susceptibility to ciprofloxacin. A model found that adding a $50 gyrase subunit A test for asymptomatic patients screened for N. gonorrhoeae resulted in cost neutrality. When ciprofloxacin susceptibility was high, a $114 test resulted in savings.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results